United Kingdom Human Recombinant Insulin Market Insight
The United Kingdom Human Recombinant Insulin Market is growing at an 5.1%CAGR, driven by rising diabetes prevalence, NHS-supported insulin access programs, and continued demand for cost-effective biologic insulin therapies.
United Kingdom Human Recombinant Insulin Market Insights Forecasts to 2035
- The United KingdomHuman Recombinant Insulin Market Size Was Estimated at USD 912.3Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.1% from 2025 to 2035
- The United KingdomHuman Recombinant Insulin Market Size is Expected to Reach USD 1500.2Million by 2035
Notable Insights for United Kingdom Human Recombinant Insulin Market
- By insulin type, regular human insulin dominated, accounting for approximately 55–60% share in 2024, due to affordability and widespread NHS usage.
- By application, Type 2 diabetes held approximately 65–70% share, driven by high disease prevalence and long-term insulin therapy needs.
- Around 75–80% of NHS insulin prescriptions include recombinant human insulin or biosimilar equivalents, supporting cost-effective diabetes management.
- Approximately 60–65% of patients prefer recombinant insulin due to lower cost compared to insulin analogues, despite slower onset of action.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Human Recombinant Insulin Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Human Recombinant Insulin Market
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon Biologics
- Wockhardt
- Pfizer
- AstraZeneca
- Novartis
- Others
Recent Developments:
- In May 2025, UK-based Arecor is advancing ultra-rapid and ultra-concentrated insulin candidates in clinical trials, designed for automated pump use and faster glucose control, improving glycemic management in diabetes patients.
- In November 2024, Novo Nordisk is gradually restructuring its insulin portfolio, shifting away from some human insulin pen formats toward vials and prioritizing insulin analogues and GLP-1 therapies to optimize global supply strategy.
Market Segmentation:
United Kingdom Human Recombinant Insulin Market, By Product Type
- Regular Human Insulin
- NPH (Intermediate-Acting Insulin)
- Premixed Human Insulin
- Short-Acting Insulin
United Kingdom Human Recombinant Insulin Market, By Application
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
United Kingdom Human Recombinant Insulin Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Diabetes Care Centers
United Kingdom Human Recombinant Insulin Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Expert Views:
The UK Human Recombinant Insulin Market is expected to grow steadily due to strong NHS adoption, affordability advantages, and widespread use in Type 2 diabetes management. Experts highlight biosimilars as a key growth driver, improving accessibility and reducing healthcare costs. While insulin analogues are gaining traction, recombinant human insulin remains essential for cost-sensitive patient groups. Continued investment in local production and supply stability will support long-term market growth through 2035.